Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161382 | 0.95 | CES2 (0.35) | CES2CES1HDAC8HDAC6NOS2 | |
| SCHEMBL4167990 | 0.90 | — | — | |
| SCHEMBL6312831 | 0.71 | CES2 (0.46) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL4154940 | 0.71 | DPP4 (0.41) | CES2CES1EPHX1 | |
| SCHEMBL7462133 | 0.68 | EPHX1 (0.44) | CES2CES1EPHX1ALDH1A1 | |
| SCHEMBL8391169 | 0.68 | EPHX1 (0.39) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL1911562 | 0.67 | CES2 (0.46) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL8396189 | 0.67 | — | — | |
| SCHEMBL22986742 | 0.67 | CES2 (0.40) | CES2CES1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL8395750 | 0.67 | EPHX1 (0.43) | CES2CES1HDAC8HDAC6EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7423172-B2 | Tyrosine derivatives as PPAR-γ-modulators | LABORATORIOS SALVAT, S.A. (ES) | 2008-09-09 | — | — | US | disclosed |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | LABORATORIES SALVAT, S.A. (ES) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | CES2 1150/4885CES1 667/4885HDAC8 2381/4885 |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | PPARG, PPARD, PPARA | CES2 1254/4885CES1 859/4885HDAC8 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.